US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Invivyd, Inc.

0.8378

+0.191729.67%

Pre-market: 0.91870.0809+9.66%05:24 EDT

Volume:5.47M

Turnover:4.27M

Market Cap:100.50M

PE:-0.58

High:0.8600

Open:0.7060

Low:0.6700

Close:0.6461

Loading ...

Overview Company News Filings

FDA Declined Invivyd’s Request to Expand Existing Emergency Use Authorization of PEMGARDA™ (pemivibart) to Include Treatment of Mild-to-Moderate COVID-19 For Immunocompromised Persons Who Have No Alternative Therapeutic Options; No Change to the Existing PEMGARDA EUA for Pre-Exposure Prophylaxis of COVID-19 in Certain Immunocompromised Patients

Why Invivyd, Inc. (IVVD) Is Soaring This Year So Far

Invivyd partners with football coach Jim Harbaugh for COVID-19 risk awareness

Invivyd Announces Partnership With Pro Football Coach Jim Harbaugh to Elevate Awareness and Ongoing Impact of Covid-19: Common, Not a Cold

THOMSON REUTERS

Invivyd Shares Soar Premarket After Tripling Monday Following Initial Results From COVID-19 Vaccination Alternative

MT Newswires Live

Invivyd Is Maintained at Buy by D. Boral Capital

Invivyd Announces Positive Phase 1/2 Clinical Data for Vyd2311, a Monoclonal Antibody Designed to Be a Superior Alternative to Covid-19 Vaccination for the Broad Population

THOMSON REUTERS

Invivyd Inc - Vyd2311 Has Favorable Safety and Tolerability

THOMSON REUTERS

Invivyd Inc - Positive Phase 1/2 Data for Vyd2311 on Safety and Pharmacokinetics

THOMSON REUTERS

Invivyd Inc - Vyd2311 Suitable as Long-Acting Covid-19 Treatment Option

THOMSON REUTERS

Invivyd Announces Positive Phase 1/2 Clinical Data for VYD2311, a Monoclonal Antibody Designed to be a Superior Alternative to COVID-19 Vaccination for the Broad Population

Invivyd Inc: Reiterates Goal of Near-Term Profitability

THOMSON REUTERS

Invivyd Announces Preliminary Fourth Quarter 2024 Financial Results, Strong Revenue Growth, and Reiterates Goal of Near-Term Profitability

We Might See A Profit From Invivyd, Inc. (NASDAQ:IVVD) Soon

Simply Wall St.

Invivyd Is Maintained at Buy by D. Boral Capital

Invivyd Provides Another Positive Sars-Cov-2 Variant Data Analysis to Satisfy U.S. FDA’s Gating Request for Completing Its Review of Eua Request for Pemgarda™ (Pemivibart) for the Treatment of Mild-to-Moderate Covid-19 in Certain Immunocompromised Patients

THOMSON REUTERS

Invivyd Provides Another Positive SARS-CoV-2 Variant Data Analysis to Satisfy U.S. FDA’s Gating Request for Completing Its Review of EUA Request for PEMGARDA™ (pemivibart) for the Treatment of Mild-to-Moderate COVID-19 in Certain Immunocompromised Patients

What's Going On With COVID-19 Antibody Developer Invivyd Stock On Friday?

Invivyd Is Maintained at Buy by D. Boral Capital

Invivyd announces continued neutralizing activity of PEMGARDA

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/IVVD/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IVVD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IVVD\",,,,,undefined,":{"symbol":"IVVD","market":"US","secType":"STK","nameCN":"Invivyd, Inc.","latestPrice":0.8378,"timestamp":1747080000000,"preClose":0.6461,"halted":0,"volume":5472213,"hourTrading":{"tag":"盘前","latestPrice":0.9187,"preClose":0.8378,"latestTime":"05:24 EDT","volume":31186,"amount":29482.02315624,"timestamp":1747128293162},"delay":0,"floatShares":47996766,"shares":119961445,"eps":-1.4333,"marketStatus":"Pre-Mkt","change":0.1917,"latestTime":"05-13 05:25:47 EDT","open":0.706,"high":0.86,"low":0.67,"amount":4267813.55780829,"amplitude":0.294072,"askPrice":0.9375,"askSize":314,"bidPrice":0.918,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.4333,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1747143000000},"marketStatusCode":1,"adr":0,"listingDate":1628222400000,"exchange":"NASDAQ","adjPreClose":0.8378,"preHourTrading":{"tag":"盘前","latestPrice":0.9187,"preClose":0.8378,"latestTime":"05:24 EDT","volume":31186,"amount":29482.02315624,"timestamp":1747128293162},"postHourTrading":{"tag":"盘后","latestPrice":0.8499,"preClose":0.8378,"latestTime":"19:59 EDT","volume":121765,"amount":102020.1254,"timestamp":1747094390918},"volumeRatio":1.4879533492453747,"impliedVol":3.1407,"impliedVolPercentile":0.9558},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IVVD\",,,,,undefined,":{"symbol":"IVVD","floatShares":47996766,"roa":"-61.64%","roe":"-138.71%","lyrEps":-1.4333,"volumeRatio":1.4879533492453747,"shares":119961445,"dividePrice":0,"high":0.86,"amplitude":0.294072,"preClose":0.6461,"low":0.67,"week52Low":0.3546,"pbRate":"1.49","psRate":"3.96","week52High":2.74,"institutionHeld":0,"latestPrice":0.8378,"committee":-0.516908,"eps":-1.4333,"divideRate":0,"volume":5472213,"delay":0,"ttmEps":-1.4333,"open":0.706,"prevYearClose":0.4431,"prevWeekClose":0.6461,"prevMonthClose":0.6302,"prevQuarterClose":0.6053,"fiveDayClose":0.5754,"twentyDayClose":0.549,"sixtyDayClose":1.38,"earningDate":1747238400000,"earningTime":"盘前"},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IVVD\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2513017728","title":"FDA Declined Invivyd’s Request to Expand Existing Emergency Use Authorization of PEMGARDA™ (pemivibart) to Include Treatment of Mild-to-Moderate COVID-19 For Immunocompromised Persons Who Have No Alternative Therapeutic Options; No Change to the Existing PEMGARDA EUA for Pre-Exposure Prophylaxis of COVID-19 in Certain Immunocompromised Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2513017728","media":"GlobeNewswire","labels":["policyRegulatory","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513017728?lang=en_us&edition=fundamental","pubTime":"2025-02-24 20:05","pubTimestamp":1740398700,"startTime":"0","endTime":"0","summary":"FDA’s reasoning appears to center on a belief that COVID-19 treatment immunobridging analyses for a monoclonal antibody  must meet a standard of superior antiviral activity rather than equivalent antiviral activity to past, highly effective, previously authorized and now inactive COVID-19 mAbs in a bridging analysis of sVNA1 titer levels, otherwise the Agency is “unable to reasonably conclude that the known and potential benefits of pemivibart…outweigh the known and potential risks”。“This is a sad day for patients in need. Immunocompromised people who cannot access standard of care are once again left with no option for COVID-19 treatment. Pemivibart, in contrast to all other COVID-19 antibodies ever made, is active and in clinical use today in the U.S. as authorized. Pemivibart is safe enough for certain immunocompromised patients who are not currently sick with COVID-19, but it is now being withheld from those same immunocompromised patients fighting active COVID-19 infection purport","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-declined-invivyd-request-expand-120500563.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory,merge","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4548","BK4585","BK4551","BNTX","BK4535","BK4568","BK4588","IVVD","BK4139"],"gpt_icon":0},{"id":"2512924164","title":"Why Invivyd, Inc. (IVVD) Is Soaring This Year So Far","url":"https://stock-news.laohu8.com/highlight/detail?id=2512924164","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512924164?lang=en_us&edition=fundamental","pubTime":"2025-02-18 23:27","pubTimestamp":1739892454,"startTime":"0","endTime":"0","summary":"Nine micro-cap companies and one small-cap firm have been the standout performers on the stock market year-to-date, having registered whopping gains between 200 to 1,200 percent since the start of the year.The list was based on the firms’ share price data from the companies’ closing prices on December 31—the last trading day of 2024—to February 14, 2025.Invivyd, Inc.  saw its year-to-date share prices rally by 263 percent to end Friday’s trading at $1.61 versus the 44 cents registered last December 31, as investor sentiment continues to be fueled by positive developments from its clinical trials.The result further supported the effectiveness of Invivyd, Inc.’s monoclonal antibodies, including Pemgarda .Invivyd, Inc.  officially submitted its latest findings to the Food and Drug Administration , and is expected to update the Pemgarda fact sheet for healthcare providers soon.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-invivyd-inc-ivvd-soaring-152734168.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PSQ","NQmain","NVIW.SI","SQQQ","USAW.SI","IVVD","TSYW.SI","BK4139","TQQQ","QID","QLD","MNQmain",".IXIC","USJW.SI"],"gpt_icon":1},{"id":"2509282785","title":"Invivyd partners with football coach Jim Harbaugh for COVID-19 risk awareness","url":"https://stock-news.laohu8.com/highlight/detail?id=2509282785","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509282785?lang=en_us&edition=fundamental","pubTime":"2025-02-05 22:35","pubTimestamp":1738766108,"startTime":"0","endTime":"0","summary":"Invivyd (IVVD) announced a strategic partnership with professional football coach Jim Harbaugh to raise awareness about the ongoing short and poten...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/invivyd-partners-with-football-coach-jim-harbaugh-for-covid-19-risk-awareness?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/invivyd-partners-with-football-coach-jim-harbaugh-for-covid-19-risk-awareness?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BNTX","BK4548","BK4535","BK4551","BK4588","IVVD","BK4568","BK4585"],"gpt_icon":0},{"id":"2509284378","title":"Invivyd Announces Partnership With Pro Football Coach Jim Harbaugh to Elevate Awareness and Ongoing Impact of Covid-19: Common, Not a Cold","url":"https://stock-news.laohu8.com/highlight/detail?id=2509284378","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509284378?lang=en_us&edition=fundamental","pubTime":"2025-02-05 22:30","pubTimestamp":1738765818,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250205:nTUA8NMVCL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IVVD"],"gpt_icon":0},{"id":"2508570431","title":"Invivyd Shares Soar Premarket After Tripling Monday Following Initial Results From COVID-19 Vaccination Alternative","url":"https://stock-news.laohu8.com/highlight/detail?id=2508570431","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508570431?lang=en_us&edition=fundamental","pubTime":"2025-02-04 18:30","pubTimestamp":1738665002,"startTime":"0","endTime":"0","summary":"Invivyd  shares extended gains in premarket activity Tuesday after the company disclosed \"positive\" data from an ongoing phase 1/2 trial of a monoclonal antibody candidate designed to be a \"superior alternative\" to COVID-19 vaccination for the broad population.Phase 1/2 clinical data for VYD2311 to date were \"positive\" for both safety and pharmacokinetics and supported by antiviral activity, the company said Monday. Pooled, blinded adverse events to date were \"mild or moderate.\" As of Day 65, serum concentrations remained high with a half-life not yet reached, indicating the potential long clinical dosing interval.Invivyd said the trial has fully enrolled, and all planned doses have been administered, with only long-term follow-up remaining.The company added that VYD2311 is designed to be \"frontline\" protection in a convenient form while providing a \"potent, long-acting option for the treatment of COVID-19.\"Invivyd shares traded 26% higher in premarket activity after almost tripling in","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4568","BK4585","BNTX","BK4548","IVVD","BK4551","BK4535","BK4588"],"gpt_icon":1},{"id":"2508018148","title":"Invivyd Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2508018148","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508018148?lang=en_us&edition=fundamental","pubTime":"2025-02-03 21:22","pubTimestamp":1738588920,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IVVD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 03, 2025 08:22 ET (13:22 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IVVD"],"gpt_icon":0},{"id":"2508147671","title":"Invivyd Announces Positive Phase 1/2 Clinical Data for Vyd2311, a Monoclonal Antibody Designed to Be a Superior Alternative to Covid-19 Vaccination for the Broad Population","url":"https://stock-news.laohu8.com/highlight/detail?id=2508147671","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508147671?lang=en_us&edition=fundamental","pubTime":"2025-02-03 20:00","pubTimestamp":1738584002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250203:nTUASLG5H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IVVD"],"gpt_icon":0},{"id":"2508147411","title":"Invivyd Inc - Vyd2311 Has Favorable Safety and Tolerability","url":"https://stock-news.laohu8.com/highlight/detail?id=2508147411","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508147411?lang=en_us&edition=fundamental","pubTime":"2025-02-03 20:00","pubTimestamp":1738584002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250203:nTUASLG5H:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IVVD"],"gpt_icon":0},{"id":"2508114786","title":"Invivyd Inc - Positive Phase 1/2 Data for Vyd2311 on Safety and Pharmacokinetics","url":"https://stock-news.laohu8.com/highlight/detail?id=2508114786","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508114786?lang=en_us&edition=fundamental","pubTime":"2025-02-03 20:00","pubTimestamp":1738584002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250203:nTUASLG5H:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IVVD","BK4139"],"gpt_icon":0},{"id":"2508114740","title":"Invivyd Inc - Vyd2311 Suitable as Long-Acting Covid-19 Treatment Option","url":"https://stock-news.laohu8.com/highlight/detail?id=2508114740","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508114740?lang=en_us&edition=fundamental","pubTime":"2025-02-03 20:00","pubTimestamp":1738584002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250203:nTUASLG5H:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IVVD","BK4139"],"gpt_icon":0},{"id":"2508114050","title":"Invivyd Announces Positive Phase 1/2 Clinical Data for VYD2311, a Monoclonal Antibody Designed to be a Superior Alternative to COVID-19 Vaccination for the Broad Population","url":"https://stock-news.laohu8.com/highlight/detail?id=2508114050","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508114050?lang=en_us&edition=fundamental","pubTime":"2025-02-03 20:00","pubTimestamp":1738584000,"startTime":"0","endTime":"0","summary":"Recruitment completed and all doses administered for VYD2311 ongoing Phase 1/2 clinical trial  evaluating 3 routes of administration. Phase 1/2 clinical data for VYD2311 to date are positive for both safety and pharmacokinetics, and are supported by antiviral activity data from Invivyd's standard virologic assessments. As of Day 65, serum concentrations remain high with half-life not yet reached, indicating potential long clinical dosing interval. In vitro neutralization potency of VYD2311 assessed across contemporary SARS-CoV-2 variants tested shows an average 17-fold greater neutralization potency than pemivibart. Phase 1/2 clinical data, combined with antiviral assessment and COVID-19 antiviral correlate of protection data, including Invivyd's Phase 3 CANOPY clinical trial data for pemivibart, support a potential clinical profile for VYD2311 with superior efficacy, safety, and durability to COVID-19 vaccines:. More favorable safety and tolerability and, since VYD2311 is not a vaccin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/invivyd-announces-positive-phase-1-120000411.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","BK4181","BK4218","BK4548","BK4585","IVVD","BK4551","BK4535","BNTX","BK4139","BK4568","PK"],"gpt_icon":0},{"id":"2508114140","title":"Invivyd Inc: Reiterates Goal of Near-Term Profitability","url":"https://stock-news.laohu8.com/highlight/detail?id=2508114140","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508114140?lang=en_us&edition=fundamental","pubTime":"2025-02-03 19:55","pubTimestamp":1738583740,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250203:nFWN3OU0SB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IVVD","BK4139"],"gpt_icon":0},{"id":"2508114061","title":"Invivyd Announces Preliminary Fourth Quarter 2024 Financial Results, Strong Revenue Growth, and Reiterates Goal of Near-Term Profitability","url":"https://stock-news.laohu8.com/highlight/detail?id=2508114061","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508114061?lang=en_us&edition=fundamental","pubTime":"2025-02-03 19:55","pubTimestamp":1738583700,"startTime":"0","endTime":"0","summary":"Preliminary Q4 2024 PEMGARDA  net product revenue of $13.8 million, 48% growth over Q3 2024 net product revenue of $9.3 million. Preliminary Q4 2024 total operating costs and expenses of approximately $32 million, 55% reduction compared to Q3 2024 operating costs and expenses of $71.6 million. Preliminary ending 2024 cash and cash equivalents of $69.3 million and $10.9 million of accounts receivable. Continues to target near-term  profitability with existing cash and cash equivalents, anticipated growth of net product revenue, and continued reduction of manufacturing expenses. About PEMGARDAPEMGARDA is a half-life extended investigational monoclonal antibody . PEMGARDA was engineered from adintrevimab, Invivyd's investigational mAb that has a robust safety data package and provided evidence of clinical efficacy in global Phase 2/3 clinical tria","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/invivyd-announces-preliminary-fourth-quarter-115500442.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IVVD"],"gpt_icon":0},{"id":"2507412016","title":"We Might See A Profit From Invivyd, Inc. (NASDAQ:IVVD) Soon","url":"https://stock-news.laohu8.com/highlight/detail?id=2507412016","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507412016?lang=en_us&edition=fundamental","pubTime":"2025-01-30 19:16","pubTimestamp":1738235817,"startTime":"0","endTime":"0","summary":"Invivyd, Inc.  is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company’s loss has recently broadened since it announced a US$199m loss in the full financial year, compared to the latest trailing-twelve-month loss of US$225m, moving it further away from breakeven. Many investors are wondering about the rate at which Invivyd will turn a profit, with the big question being “when will the company breakeven?”Below we will provide a high-level summary of the industry analysts’ expectations for the company.According to the 4 industry analysts covering Invivyd, the consensus is that breakeven is near. They expect the company to post a final loss in 2024, before turning a profit of US$25m in 2025. So, the company is predicted to brea","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/might-see-profit-invivyd-inc-111657095.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NQmain","BK4139","USJW.SI","IE00BKPKM429.USD","NVIW.SI","NDAQ","MNQmain",".IXIC","IE00B64PRP62.GBP","TSYW.SI","LU2210149790.SGD","BK4112","IE00B3QW5Z07.USD","QLD","USAW.SI","IVVD","IE00BGHQF748.EUR","PSQ","LU2210150020.SGD","LU2095319765.USD","QID","SQQQ","BK4585","BK4588","TQQQ"],"gpt_icon":1},{"id":"2506065333","title":"Invivyd Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2506065333","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506065333?lang=en_us&edition=fundamental","pubTime":"2025-01-27 23:01","pubTimestamp":1737990060,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IVVD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 27, 2025 10:01 ET (15:01 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IVVD"],"gpt_icon":0},{"id":"2506376503","title":"Invivyd Provides Another Positive Sars-Cov-2 Variant Data Analysis to Satisfy U.S. FDA’s Gating Request for Completing Its Review of Eua Request for Pemgarda™ (Pemivibart) for the Treatment of Mild-to-Moderate Covid-19 in Certain Immunocompromised Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2506376503","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506376503?lang=en_us&edition=fundamental","pubTime":"2025-01-27 20:07","pubTimestamp":1737979628,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250127:nFWN3ON0P8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IVVD","BK4139"],"gpt_icon":0},{"id":"2506076375","title":"Invivyd Provides Another Positive SARS-CoV-2 Variant Data Analysis to Satisfy U.S. FDA’s Gating Request for Completing Its Review of EUA Request for PEMGARDA™ (pemivibart) for the Treatment of Mild-to-Moderate COVID-19 in Certain Immunocompromised Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2506076375","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506076375?lang=en_us&edition=fundamental","pubTime":"2025-01-27 20:01","pubTimestamp":1737979260,"startTime":"0","endTime":"0","summary":"Treatment immunobridging analysis, routinely updated for contemporary SARS-CoV-2 variants, compares pemivibart antiviral titers to adintrevimab antiviral titers from the company’s previous Phase 2/3 clinical trial of adintrevimab for the treatment of COVID-19 , in which adintrevimab conferred a 66% to 74% reduction in risk of hospitalization or death from COVID-19 compared to placebo depending on time of therapy start. Most recent updated analysis provided to FDA, incorporating current dominant SARS-CoV-2 variant XEC neutralization data, demonstrated substantially higher pemivibart titers in the critical early phase post-dosing  as compared to adintrevimab. Pemivibart safety profile demonstrated in the company’s CANOPY Phase 3 clinical trial supports the EUA amendment request; further, no additional reports of anaphylaxis have been identified during post-authorization use of PEMGARDA for COVID-19 pre-exposure prophylaxis  to date. Updated analysis builds upon multiple comparable analys","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/invivyd-provides-another-positive-sars-120100787.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4551","BK4535","BK4548","BK4568","BK4585","IVVD","BK4588","BK4139","BNTX"],"gpt_icon":0},{"id":"2502890506","title":"What's Going On With COVID-19 Antibody Developer Invivyd Stock On Friday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2502890506","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502890506?lang=en_us&edition=fundamental","pubTime":"2025-01-11 01:12","pubTimestamp":1736529159,"startTime":"0","endTime":"0","summary":"On Friday, Invivyd Inc.  announced that new in vitro neutralization data show continued neutralizing activity of Pemgarda and pipeline candidate VYD2311 against dominant SARS-CoV-2 variant XEC.The stock is trading with a strong session volume of 12.3 million, compared to an average volume of 757.02k as per data from Benzinga Pro.As anticipated, the data are largely consistent with those previously reported for KP.3.1.1, based on the structural biology of pemivibart and VYD2311.The Centers for Disease Control  estimates that XEC and KP.3.1.1 accounted for an aggregate 69% of U.S. circulating variants of SARS-CoV-2 for the two weeks ended December 21, 2024.Invivyd generated these new data as part of its ongoing industrial virology effort. It leverages a third-party pseudoviral system that routinely tests authentic Invivyd-produced pemivibart and is supported by extensive structure-based and proprietary analytics.Further, the company estimates that every clinical variant reported in the C","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/whats-going-covid-19-antibody-171239951.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CDC","IVVD","BK4139","BNTX"],"gpt_icon":0},{"id":"2502863305","title":"Invivyd Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2502863305","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502863305?lang=en_us&edition=fundamental","pubTime":"2025-01-10 21:09","pubTimestamp":1736514540,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IVVD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 10, 2025 08:09 ET (13:09 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IVVD"],"gpt_icon":0},{"id":"2502852406","title":"Invivyd announces continued neutralizing activity of PEMGARDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2502852406","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502852406?lang=en_us&edition=fundamental","pubTime":"2025-01-10 20:15","pubTimestamp":1736511322,"startTime":"0","endTime":"0","summary":"Invivyd (IVVD) announced that new in vitro neutralization data show continued neutralizing activity of PEMGARDA and pipeline candidate VYD2311 agai...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/invivyd-announces-continued-neutralizing-activity-of-pemgarda?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/invivyd-announces-continued-neutralizing-activity-of-pemgarda?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IVVD","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":72,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IVVD\",params:#limit:5,,,undefined,":[{"date":"2025-05-15","symbol":"IVVD","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2025/03","expectedEps":-0.04,"defaultRemindTime":1747296000000,"name":null,"time":"Pre-Market","dateTimestamp":1747281600000,"actualEps":null},{"market":"US","date":"2025-03-20","symbol":"IVVD","fiscalQuarterEnding":"2024/12","expectedEps":-0.25,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1742443200000,"reportTimeType":"pre","actualEps":-0.15},{"market":"US","date":"2025-02-03","symbol":"IVVD","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1738558800000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2024-11-14","symbol":"IVVD","fiscalQuarterEnding":"2024/09","expectedEps":-0.33,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"pre","actualEps":-0.51},{"date":"2024-10-29","symbol":"IVVD","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1730188800000,"name":null,"time":"Pre-Market","dateTimestamp":1730174400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IVVD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IVVD\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.6667,"hold":0.3333,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":3,"updateTime":1730520000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/IVVD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"IVVD","date":"2025-05-12","current":-0.456125,"percent":0.903471,"low":-54.35026,"twenty":-2.693178,"median":-1.058529,"eighty":-0.593333,"high":-0.170743,"avg":-4.05396,"sd":9.081933,"marketCap":77507089},"quantilePoints":[{"date":"2021-08-06","current":-20.235974,"twenty":-12.209882,"median":-0.170743,"eighty":-0.170743,"marketCap":2265932260},{"date":"2021-08-13","current":-25.837695,"twenty":-26.477338,"median":-22.901153,"eighty":-8.196835,"marketCap":2893187455},{"date":"2021-08-20","current":-26.787468,"twenty":-26.857247,"median":-25.973377,"eighty":-21.081078,"marketCap":2999538682},{"date":"2021-08-27","current":-29.442955,"twenty":-27.834156,"median":-26.254432,"eighty":-22.790669,"marketCap":3296888030},{"date":"2021-09-03","current":-41.082517,"twenty":-30.582682,"median":-26.903767,"eighty":-24.407221,"marketCap":4600233167},{"date":"2021-09-10","current":-52.237501,"twenty":-34.346884,"median":-27.107289,"eighty":-25.864831,"marketCap":5849317474},{"date":"2021-09-17","current":-49.87276,"twenty":-41.574848,"median":-28.333272,"eighty":-25.990822,"marketCap":5584524623},{"date":"2021-09-24","current":-43.437403,"twenty":-45.837563,"median":-31.3425,"eighty":-26.070293,"marketCap":4863922575},{"date":"2021-10-01","current":-27.799143,"twenty":-45.332177,"median":-32.752622,"eighty":-26.167208,"marketCap":3112821446},{"date":"2021-10-08","current":-34.098162,"twenty":-44.772716,"median":-31.663999,"eighty":-26.477338,"marketCap":3818156971},{"date":"2021-10-15","current":-32.220379,"twenty":-44.391197,"median":-31.942189,"eighty":-26.810728,"marketCap":3607891333},{"date":"2021-10-22","current":-33.531847,"twenty":-43.143316,"median":-32.796234,"eighty":-26.944471,"marketCap":3754743525},{"date":"2021-10-29","current":-29.050998,"twenty":-41.908316,"median":-32.394248,"eighty":-27.107289,"marketCap":3252998538},{"date":"2021-11-05","current":-19.910465,"twenty":-41.574848,"median":-31.842835,"eighty":-27.107289,"marketCap":2229483266},{"date":"2021-11-12","current":-19.016283,"twenty":-41.160049,"median":-31.463508,"eighty":-26.167208,"marketCap":2129356772},{"date":"2021-11-19","current":-10.754495,"twenty":-40.958465,"median":-30.898976,"eighty":-23.930397,"marketCap":2232820816},{"date":"2021-11-26","current":-13.460534,"twenty":-40.462257,"median":-30.670462,"eighty":-19.910465,"marketCap":2794641699},{"date":"2021-12-03","current":-24.557973,"twenty":-40.277958,"median":-30.278016,"eighty":-20.235974,"marketCap":5098663577},{"date":"2021-12-10","current":-17.806272,"twenty":-39.274486,"median":-29.442955,"eighty":-19.910465,"marketCap":3696892661},{"date":"2021-12-17","current":-6.15155,"twenty":-36.830387,"median":-28.396375,"eighty":-19.016283,"marketCap":1277169056},{"date":"2021-12-23","current":-4.640455,"twenty":-35.773265,"median":-28.318734,"eighty":-17.731253,"marketCap":963439375},{"date":"2021-12-31","current":-3.890266,"twenty":-34.889434,"median":-27.107289,"eighty":-10.888458,"marketCap":807687051},{"date":"2022-01-07","current":-3.177586,"twenty":-34.726181,"median":-26.845617,"eighty":-10.250797,"marketCap":659722343},{"date":"2022-01-14","current":-3.054341,"twenty":-34.716142,"median":-26.109059,"eighty":-6.024018,"marketCap":634134462},{"date":"2022-01-21","current":-3.370492,"twenty":-34.344559,"median":-25.973377,"eighty":-4.803353,"marketCap":699772941},{"date":"2022-01-28","current":-3.633058,"twenty":-33.758373,"median":-25.150086,"eighty":-4.146402,"marketCap":754286254},{"date":"2022-02-04","current":-4.41004,"twenty":-33.472235,"median":-24.833935,"eighty":-4.117466,"marketCap":915601161},{"date":"2022-02-11","current":-3.750945,"twenty":-33.414609,"median":-22.901153,"eighty":-4.037089,"marketCap":778761620},{"date":"2022-02-18","current":-3.440152,"twenty":-33.038815,"median":-20.249744,"eighty":-3.881692,"marketCap":714235657},{"date":"2022-02-25","current":-3.499096,"twenty":-32.761344,"median":-19.910465,"eighty":-3.803458,"marketCap":726473339},{"date":"2022-03-04","current":-2.695322,"twenty":-32.644704,"median":-19.383891,"eighty":-3.620198,"marketCap":559595849},{"date":"2022-03-11","current":-2.706039,"twenty":-32.425048,"median":-19.016283,"eighty":-3.495881,"marketCap":561820883},{"date":"2022-03-18","current":-2.663171,"twenty":-32.232302,"median":-18.082234,"eighty":-3.447654,"marketCap":552920750},{"date":"2022-03-25","current":-2.121963,"twenty":-32.069361,"median":-13.460534,"eighty":-3.399428,"marketCap":440556573},{"date":"2022-04-01","current":-2.185863,"twenty":-31.771301,"median":-10.864345,"eighty":-3.292258,"marketCap":495731781},{"date":"2022-04-08","current":-1.866688,"twenty":-31.632206,"median":-10.454419,"eighty":-3.196877,"marketCap":423346167},{"date":"2022-04-14","current":-1.736117,"twenty":-31.536113,"median":-10.036457,"eighty":-2.990039,"marketCap":393733871},{"date":"2022-04-22","current":-1.426614,"twenty":-31.313407,"median":-6.874947,"eighty":-2.80142,"marketCap":323541760},{"date":"2022-04-29","current":-1.38309,"twenty":-31.137425,"median":-5.513889,"eighty":-2.691035,"marketCap":313670994},{"date":"2022-05-06","current":-1.392762,"twenty":-30.873144,"median":-5.106644,"eighty":-2.665314,"marketCap":315864498},{"date":"2022-05-13","current":-1.033486,"twenty":-30.749945,"median":-4.774417,"eighty":-2.440927,"marketCap":298425270},{"date":"2022-05-20","current":-1.120876,"twenty":-30.64463,"median":-4.321625,"eighty":-2.212136,"marketCap":323659760},{"date":"2022-05-27","current":-1.132275,"twenty":-30.523419,"median":-4.206417,"eighty":-2.074048,"marketCap":326951215},{"date":"2022-06-03","current":-1.200668,"twenty":-30.451885,"median":-4.15819,"eighty":-1.963408,"marketCap":346699946},{"date":"2022-06-10","current":-1.124676,"twenty":-30.104147,"median":-3.970643,"eighty":-1.784476,"marketCap":324756912},{"date":"2022-06-17","current":-1.033486,"twenty":-30.05447,"median":-3.890266,"eighty":-1.562021,"marketCap":298425270},{"date":"2022-06-24","current":-1.27695,"twenty":-29.565258,"median":-3.847398,"eighty":-1.481744,"marketCap":368726981},{"date":"2022-07-01","current":-1.330156,"twenty":-29.129389,"median":-3.775058,"eighty":-1.43822,"marketCap":384090605},{"date":"2022-07-08","current":-1.569584,"twenty":-28.687364,"median":-3.66253,"eighty":-1.432587,"marketCap":453226914},{"date":"2022-07-15","current":-1.527779,"twenty":-28.386662,"median":-3.584832,"eighty":-1.439301,"marketCap":441155495},{"date":"2022-07-22","current":-1.580986,"twenty":-28.330364,"median":-3.496417,"eighty":-1.441122,"marketCap":456519119},{"date":"2022-07-29","current":-1.337757,"twenty":-28.318734,"median":-3.466945,"eighty":-1.439301,"marketCap":386285408},{"date":"2022-08-05","current":-1.520179,"twenty":-28.006979,"median":-3.442832,"eighty":-1.418008,"marketCap":438960692},{"date":"2022-08-12","current":-1.516378,"twenty":-27.384031,"median":-3.402643,"eighty":-1.425167,"marketCap":437863290},{"date":"2022-08-19","current":-1.549068,"twenty":-27.107289,"median":-3.34102,"eighty":-1.426035,"marketCap":457088205},{"date":"2022-08-26","current":-1.69291,"twenty":-26.985176,"median":-3.279398,"eighty":-1.431485,"marketCap":499532109},{"date":"2022-09-02","current":-1.762987,"twenty":-26.833988,"median":-3.247247,"eighty":-1.435834,"marketCap":520209909},{"date":"2022-09-09","current":-1.696599,"twenty":-26.632403,"median":-3.150793,"eighty":-1.43839,"marketCap":500620415},{"date":"2022-09-16","current":-1.416291,"twenty":-26.283507,"median":-2.973964,"eighty":-1.43839,"marketCap":417909216},{"date":"2022-09-23","current":-1.095413,"twenty":-26.089676,"median":-2.842681,"eighty":-1.425167,"marketCap":323226659},{"date":"2022-09-30","current":-1.166035,"twenty":-26.025711,"median":-2.786416,"eighty":-1.403926,"marketCap":344065403},{"date":"2022-10-07","current":-1.188387,"twenty":-25.919104,"median":-2.692642,"eighty":-1.367291,"marketCap":350660906},{"date":"2022-10-14","current":-1.221915,"twenty":-25.585157,"median":-2.679246,"eighty":-1.335295,"marketCap":360554160},{"date":"2022-10-21","current":-1.370929,"twenty":-25.161339,"median":-2.598869,"eighty":-1.327097,"marketCap":404524180},{"date":"2022-10-28","current":-1.464063,"twenty":-25.020946,"median":-2.452181,"eighty":-1.331555,"marketCap":432005442},{"date":"2022-11-04","current":-1.318774,"twenty":-24.880554,"median":-2.304152,"eighty":-1.330032,"marketCap":389134673},{"date":"2022-11-11","current":-1.402279,"twenty":-24.72355,"median":-2.205207,"eighty":-1.330032,"marketCap":392336643},{"date":"2022-11-18","current":-1.071185,"twenty":-24.116213,"median":-2.120061,"eighty":-1.321288,"marketCap":299701602},{"date":"2022-11-25","current":-0.833577,"twenty":-23.232604,"median":-2.052303,"eighty":-1.304144,"marketCap":233222338},{"date":"2022-12-02","current":-0.903691,"twenty":-22.029676,"median":-1.963408,"eighty":-1.287526,"marketCap":252839170},{"date":"2022-12-09","current":-0.771253,"twenty":-20.652703,"median":-1.869106,"eighty":-1.273678,"marketCap":215785153},{"date":"2022-12-16","current":-0.631026,"twenty":-20.24699,"median":-1.781428,"eighty":-1.254406,"marketCap":176551489},{"date":"2022-12-23","current":-0.662187,"twenty":-20.170872,"median":-1.761143,"eighty":-1.246835,"marketCap":185270081},{"date":"2022-12-30","current":-0.584283,"twenty":-19.910465,"median":-1.729267,"eighty":-1.233091,"marketCap":163473601},{"date":"2023-01-06","current":-0.646606,"twenty":-19.910465,"median":-1.709507,"eighty":-1.220425,"marketCap":180910785},{"date":"2023-01-13","current":-0.864739,"twenty":-19.727655,"median":-1.700287,"eighty":-1.204982,"marketCap":241940930},{"date":"2023-01-20","current":-0.705035,"twenty":-19.324279,"median":-1.696599,"eighty":-1.18418,"marketCap":197258145},{"date":"2023-01-27","current":-0.966014,"twenty":-19.073908,"median":-1.680001,"eighty":-1.168577,"marketCap":270276354},{"date":"2023-02-03","current":-0.817996,"twenty":-19.036154,"median":-1.663404,"eighty":-1.145789,"marketCap":228863042},{"date":"2023-02-10","current":-0.697244,"twenty":-18.849703,"median":-1.652339,"eighty":-1.126955,"marketCap":195078497},{"date":"2023-02-17","current":-0.759568,"twenty":-18.510377,"median":-1.599988,"eighty":-1.120876,"marketCap":212515681},{"date":"2023-02-24","current":-0.669978,"twenty":-18.137426,"median":-1.580986,"eighty":-1.092453,"marketCap":187449729},{"date":"2023-03-03","current":-0.681663,"twenty":-17.656234,"median":-1.570639,"eighty":-1.028927,"marketCap":190719201},{"date":"2023-03-10","current":-0.689454,"twenty":-15.84292,"median":-1.562021,"eighty":-1.00081,"marketCap":192898849},{"date":"2023-03-17","current":-0.588178,"twenty":-12.481002,"median":-1.538592,"eighty":-0.965462,"marketCap":164563425},{"date":"2023-03-24","current":-0.592742,"twenty":-10.968835,"median":-1.527779,"eighty":-0.894342,"marketCap":143038670},{"date":"2023-03-31","current":-0.54297,"twenty":-10.872382,"median":-1.517437,"eighty":-0.884215,"marketCap":131027790},{"date":"2023-04-06","current":-0.538445,"twenty":-10.810224,"median":-1.510673,"eighty":-0.88032,"marketCap":129935891},{"date":"2023-04-14","current":-0.534538,"twenty":-10.69448,"median":-1.497376,"eighty":-0.857727,"marketCap":128993146},{"date":"2023-04-21","current":-0.539068,"twenty":-10.424412,"median":-1.489775,"eighty":-0.829682,"marketCap":130086308},{"date":"2023-04-28","current":-0.511888,"twenty":-10.250797,"median":-1.484646,"eighty":-0.81488,"marketCap":123527335},{"date":"2023-05-05","current":-0.534538,"twenty":-10.004306,"median":-1.471564,"eighty":-0.788392,"marketCap":128993146},{"date":"2023-05-12","current":-0.888336,"twenty":-9.42023,"median":-1.465302,"eighty":-0.768137,"marketCap":156322203},{"date":"2023-05-19","current":-0.777692,"twenty":-7.308984,"median":-1.45367,"eighty":-0.771253,"marketCap":136852082},{"date":"2023-05-26","current":-0.914566,"twenty":-6.075459,"median":-1.441122,"eighty":-0.771297,"marketCap":160938049},{"date":"2023-06-02","current":-0.933231,"twenty":-5.771097,"median":-1.436569,"eighty":-0.771471,"marketCap":164222499},{"date":"2023-06-09","current":-0.839908,"twenty":-5.513889,"median":-1.428574,"eighty":-0.777692,"marketCap":147800249},{"date":"2023-06-16","current":-0.796357,"twenty":-5.358493,"median":-1.425167,"eighty":-0.783914,"marketCap":140136532},{"date":"2023-06-23","current":-0.659483,"twenty":-5.277043,"median":-1.40727,"eighty":-0.771253,"marketCap":116050565},{"date":"2023-06-30","current":-0.703034,"twenty":-5.076636,"median":-1.402434,"eighty":-0.766514,"marketCap":123714282},{"date":"2023-07-07","current":-0.696812,"twenty":-4.903021,"median":-1.400732,"eighty":-0.759568,"marketCap":122619465},{"date":"2023-07-14","current":-0.858572,"twenty":-4.803353,"median":-1.392762,"eighty":-0.759568,"marketCap":151084699},{"date":"2023-07-21","current":-0.902123,"twenty":-4.720832,"median":-1.38309,"eighty":-0.76184,"marketCap":158748415},{"date":"2023-07-28","current":-0.902123,"twenty":-4.548289,"median":-1.369067,"eighty":-0.766093,"marketCap":158748415},{"date":"2023-08-04","current":-0.920788,"twenty":-4.339308,"median":-1.356759,"eighty":-0.767358,"marketCap":162032865},{"date":"2023-08-11","current":-0.964339,"twenty":-4.226779,"median":-1.354805,"eighty":-0.768916,"marketCap":169696582},{"date":"2023-08-18","current":-1.071184,"twenty":-4.212847,"median":-1.341126,"eighty":-0.771253,"marketCap":187682117},{"date":"2023-08-25","current":-1.115033,"twenty":-4.206417,"median":-1.331904,"eighty":-0.77134,"marketCap":195365010},{"date":"2023-09-01","current":-1.165147,"twenty":-4.187126,"median":-1.325058,"eighty":-0.771471,"marketCap":204145460},{"date":"2023-09-08","current":-1.108769,"twenty":-4.137828,"median":-1.318774,"eighty":-0.772715,"marketCap":194267454},{"date":"2023-09-15","current":-1.102505,"twenty":-4.046734,"median":-1.300575,"eighty":-0.778936,"marketCap":193169898},{"date":"2023-09-22","current":-1.039863,"twenty":-3.993149,"median":-1.292152,"eighty":-0.783914,"marketCap":182194335},{"date":"2023-09-29","current":-1.108769,"twenty":-3.92456,"median":-1.28265,"eighty":-0.784498,"marketCap":194267454},{"date":"2023-10-06","current":-1.02107,"twenty":-3.890266,"median":-1.27286,"eighty":-0.788392,"marketCap":178901667},{"date":"2023-10-13","current":-1.033598,"twenty":-3.885979,"median":-1.257306,"eighty":-0.794625,"marketCap":181096779},{"date":"2023-10-20","current":-0.989749,"twenty":-3.864545,"median":-1.253862,"eighty":-0.794971,"marketCap":173413885},{"date":"2023-10-27","current":-1.039863,"twenty":-3.855972,"median":-1.250062,"eighty":-0.795664,"marketCap":182194335},{"date":"2023-11-03","current":-0.970956,"twenty":-3.824892,"median":-1.24107,"eighty":-0.80009,"marketCap":170121217},{"date":"2023-11-10","current":-0.876993,"twenty":-3.803458,"median":-1.233091,"eighty":-0.803649,"marketCap":153657873},{"date":"2023-11-17","current":-0.974107,"twenty":-3.770235,"median":-1.223778,"eighty":-0.807025,"marketCap":165172440},{"date":"2023-11-24","current":-0.967613,"twenty":-3.727368,"median":-1.213951,"eighty":-0.8088,"marketCap":164071290},{"date":"2023-12-01","current":-0.993589,"twenty":-3.668424,"median":-1.20606,"eighty":-0.8088,"marketCap":168475888},{"date":"2023-12-08","current":-1.097493,"twenty":-3.624484,"median":-1.192112,"eighty":-0.81092,"marketCap":186094282},{"date":"2023-12-15","current":-1.116976,"twenty":-3.600907,"median":-1.17787,"eighty":-0.815659,"marketCap":189397731},{"date":"2023-12-22","current":-2.435267,"twenty":-3.563398,"median":-1.186164,"eighty":-0.817996,"marketCap":412931100},{"date":"2023-12-29","current":-2.545665,"twenty":-3.531247,"median":-1.195838,"eighty":-0.817996,"marketCap":431650643},{"date":"2024-01-05","current":-2.435267,"twenty":-3.511956,"median":-1.203364,"eighty":-0.820333,"marketCap":412931100},{"date":"2024-01-12","current":-2.688534,"twenty":-3.495881,"median":-1.213437,"eighty":-0.826566,"marketCap":455875934},{"date":"2024-01-19","current":-2.883356,"twenty":-3.48945,"median":-1.221915,"eighty":-0.829682,"marketCap":488910422},{"date":"2024-01-26","current":-2.876862,"twenty":-3.47659,"median":-1.233091,"eighty":-0.83124,"marketCap":487809272},{"date":"2024-02-02","current":-3.117141,"twenty":-3.460515,"median":-1.235593,"eighty":-0.833621,"marketCap":528551808},{"date":"2024-02-09","current":-3.272998,"twenty":-3.448726,"median":-1.249027,"eighty":-0.836175,"marketCap":554979398},{"date":"2024-02-16","current":-2.88069,"twenty":-3.448726,"median":-1.254147,"eighty":-0.839908,"marketCap":488458412},{"date":"2024-02-23","current":-2.831627,"twenty":-3.444439,"median":-1.259169,"eighty":-0.842397,"marketCap":480139169},{"date":"2024-03-01","current":-2.754528,"twenty":-3.436937,"median":-1.274905,"eighty":-0.852491,"marketCap":467066072},{"date":"2024-03-08","current":-2.670421,"twenty":-3.41979,"median":-1.284551,"eighty":-0.853832,"marketCap":452804513},{"date":"2024-03-15","current":-2.558277,"twenty":-3.401571,"median":-1.29463,"eighty":-0.857273,"marketCap":433789100},{"date":"2024-03-22","current":-2.165774,"twenty":-3.391926,"median":-1.301003,"eighty":-0.858572,"marketCap":367235156},{"date":"2024-03-28","current":-2.393164,"twenty":-3.370492,"median":-1.318774,"eighty":-0.858572,"marketCap":475385316},{"date":"2024-04-05","current":-2.148639,"twenty":-3.311549,"median":-1.327504,"eighty":-0.860844,"marketCap":426812003},{"date":"2024-04-12","current":-1.833545,"twenty":-3.311549,"median":-1.333653,"eighty":-0.864739,"marketCap":364220857},{"date":"2024-04-19","current":-1.410419,"twenty":-3.279398,"median":-1.341342,"eighty":-0.864794,"marketCap":280169890},{"date":"2024-04-26","current":-1.242369,"twenty":-3.274039,"median":-1.341126,"eighty":-0.864794,"marketCap":246787946},{"date":"2024-05-03","current":-1.422423,"twenty":-3.272998,"median":-1.339441,"eighty":-0.864794,"marketCap":282554315},{"date":"2024-05-10","current":-1.452432,"twenty":-3.268681,"median":-1.354074,"eighty":-0.871015,"marketCap":288515376},{"date":"2024-05-17","current":-1.412314,"twenty":-3.26001,"median":-1.355782,"eighty":-0.876993,"marketCap":292092013},{"date":"2024-05-24","current":-1.158674,"twenty":-3.225813,"median":-1.354074,"eighty":-0.877237,"marketCap":239634672},{"date":"2024-05-31","current":-1.043383,"twenty":-3.211609,"median":-1.341126,"eighty":-0.879703,"marketCap":215790426},{"date":"2024-06-07","current":-1.009596,"twenty":-3.192472,"median":-1.333025,"eighty":-0.88032,"marketCap":208802627},{"date":"2024-06-14","current":-0.98075,"twenty":-3.181982,"median":-1.330053,"eighty":-0.88032,"marketCap":202836837},{"date":"2024-06-21","current":-0.755755,"twenty":-3.174189,"median":-1.321916,"eighty":-0.87847,"marketCap":156303680},{"date":"2024-06-28","current":-0.692294,"twenty":-3.170792,"median":-1.318774,"eighty":-0.877188,"marketCap":143178944},{"date":"2024-07-05","current":-0.634603,"twenty":-3.142038,"median":-1.315549,"eighty":-0.864794,"marketCap":131247365},{"date":"2024-07-12","current":-0.674987,"twenty":-3.119885,"median":-1.301003,"eighty":-0.859935,"marketCap":139599470},{"date":"2024-07-15","current":-0.686525,"twenty":-3.118513,"median":-1.300575,"eighty":-0.858572,"marketCap":141985786},{"date":"2024-08-02","current":-0.68941,"twenty":-3.117141,"median":-1.300147,"eighty":-0.858572,"marketCap":142582365},{"date":"2024-08-09","current":-0.605758,"twenty":-3.097659,"median":-1.294588,"eighty":-0.848061,"marketCap":125281576},{"date":"2024-08-16","current":-0.60941,"twenty":-3.065189,"median":-1.28637,"eighty":-0.833577,"marketCap":124220340},{"date":"2024-08-23","current":-0.514541,"twenty":-3.055914,"median":-1.279565,"eighty":-0.817996,"marketCap":104882577},{"date":"2024-08-30","current":-0.517764,"twenty":-3.054341,"median":-1.273965,"eighty":-0.8088,"marketCap":105539512},{"date":"2024-09-06","current":-0.498896,"twenty":-3.052629,"median":-1.268761,"eighty":-0.804006,"marketCap":101693459},{"date":"2024-09-13","current":-0.673867,"twenty":-3.052201,"median":-1.254795,"eighty":-0.793067,"marketCap":137359030},{"date":"2024-09-20","current":-0.714885,"twenty":-3.043957,"median":-1.250062,"eighty":-0.776448,"marketCap":145720014},{"date":"2024-09-27","current":-0.60941,"twenty":-3.030682,"median":-1.247269,"eighty":-0.770474,"marketCap":124220340},{"date":"2024-10-04","current":-0.562884,"twenty":-3.005449,"median":-1.242369,"eighty":-0.759568,"marketCap":114736595},{"date":"2024-10-11","current":-0.529894,"twenty":-2.97914,"median":-1.234118,"eighty":-0.750739,"marketCap":108011974},{"date":"2024-10-18","current":-0.61527,"twenty":-2.95253,"median":-1.22564,"eighty":-0.739313,"marketCap":125414766},{"date":"2024-10-25","current":-0.57935,"twenty":-2.944451,"median":-1.213951,"eighty":-0.734142,"marketCap":118092933},{"date":"2024-10-31","current":-0.533292,"twenty":-2.934797,"median":-1.206537,"eighty":-0.729185,"marketCap":108704742},{"date":"2024-11-08","current":-0.585971,"twenty":-2.925172,"median":-1.195838,"eighty":-0.709709,"marketCap":119442635},{"date":"2024-11-15","current":-0.419997,"twenty":-2.922744,"median":-1.180905,"eighty":-0.703113,"marketCap":94556475},{"date":"2024-11-22","current":-0.371808,"twenty":-2.92249,"median":-1.17407,"eighty":-0.697071,"marketCap":83707301},{"date":"2024-11-29","current":-0.37117,"twenty":-2.91193,"median":-1.166035,"eighty":-0.69059,"marketCap":83563762},{"date":"2024-12-06","current":-0.303269,"twenty":-2.891149,"median":-1.165147,"eighty":-0.68557,"marketCap":68276832},{"date":"2024-12-13","current":-0.308104,"twenty":-2.88229,"median":-1.162672,"eighty":-0.679326,"marketCap":69365338},{"date":"2024-12-20","current":-0.228302,"twenty":-2.879159,"median":-1.158778,"eighty":-0.673873,"marketCap":51399010},{"date":"2024-12-27","current":-0.281805,"twenty":-2.876862,"median":-1.150014,"eighty":-0.673867,"marketCap":63444344},{"date":"2025-01-03","current":-0.255027,"twenty":-2.876862,"median":-1.146355,"eighty":-0.669978,"marketCap":57415696},{"date":"2025-01-10","current":-0.245198,"twenty":-2.874317,"median":-1.138593,"eighty":-0.663197,"marketCap":55202800},{"date":"2025-01-17","current":-0.233403,"twenty":-2.868171,"median":-1.132275,"eighty":-0.656796,"marketCap":52547324},{"date":"2025-01-24","current":-0.222245,"twenty":-2.85831,"median":-1.128781,"eighty":-0.646866,"marketCap":50035387},{"date":"2025-01-31","current":-0.207209,"twenty":-2.840038,"median":-1.124676,"eighty":-0.643039,"marketCap":46650253},{"date":"2025-02-07","current":-1.051985,"twenty":-2.823791,"median":-1.121298,"eighty":-0.64111,"marketCap":236839749},{"date":"2025-02-14","current":-0.733202,"twenty":-2.818476,"median":-1.120876,"eighty":-0.643039,"marketCap":165070128},{"date":"2025-02-21","current":-0.64288,"twenty":-2.812485,"median":-1.118477,"eighty":-0.643031,"marketCap":144735402},{"date":"2025-02-28","current":-0.658819,"twenty":-2.803591,"median":-1.116976,"eighty":-0.644411,"marketCap":148323883},{"date":"2025-03-07","current":-0.547245,"twenty":-2.801008,"median":-1.110663,"eighty":-0.636245,"marketCap":123204516},{"date":"2025-03-14","current":-0.431473,"twenty":-2.796913,"median":-1.108769,"eighty":-0.631096,"marketCap":97140182},{"date":"2025-03-21","current":-0.521427,"twenty":-2.792516,"median":-1.102505,"eighty":-0.62713,"marketCap":88603523},{"date":"2025-03-28","current":-0.43064,"twenty":-2.784875,"median":-1.097493,"eighty":-0.619015,"marketCap":73176481},{"date":"2025-04-04","current":-0.388282,"twenty":-2.77135,"median":-1.096241,"eighty":-0.613037,"marketCap":65978794},{"date":"2025-04-11","current":-0.356513,"twenty":-2.754107,"median":-1.09048,"eighty":-0.611536,"marketCap":60580529},{"date":"2025-04-17","current":-0.332722,"twenty":-2.752176,"median":-1.083864,"eighty":-0.609696,"marketCap":56537829},{"date":"2025-04-25","current":-0.471868,"twenty":-2.738793,"median":-1.080862,"eighty":-0.606488,"marketCap":80182229},{"date":"2025-05-02","current":-0.428663,"twenty":-2.703896,"median":-1.071184,"eighty":-0.598126,"marketCap":72840589},{"date":"2025-05-09","current":-0.416521,"twenty":-2.69425,"median":-1.060024,"eighty":-0.594913,"marketCap":70777252},{"date":"2025-05-12","current":-0.456125,"twenty":-2.693178,"median":-1.058529,"eighty":-0.593333,"marketCap":77507089}],"updateTime":1747128347167}}}